USFDA grants Breakthrough Designation for blood test to help diagnose inaccessible brain tumours
Datar Cancer Genetics (DCG) has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its ‘TriNetra-Glio’, a blood test to help in the diagnosis of brain tumours. This is the third test...